Posted by Michael Wonder on 24 Dec 2019
Teligent announces FDA request for further data on complex drug
23 December 2019 - Teligent today announced its development partner has received a complete response letter from the U.S. FDA for its abbreviated new drug application for its first complex drug indicated for an orphan disease population.
In the letter, the FDA requested further information and raw data to support the application.
